Huang Wenjie, Zhang Yu, Li Hao, Liang Zhiying, Zhou Shumin, Pan Jie, Xie Hui, Luo Chao, Li Shuqi, Ruan Guangying, Ai Fei, Chen Yanfeng
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Cancer Med. 2024 Dec;13(24):e70493. doi: 10.1002/cam4.70493.
To investigate the impact of the number of positive lymph nodes (PLNs) on long-term survival and pathological nodal stage in patients with oral tongue squamous cell carcinoma (OTSCC).
Newly diagnosed and nonmetastatic adult patients with OTSCC who underwent curative resection were identified between January 2010 and December 2020. External validation was performed via the SEER registry. Multivariate Cox proportional hazards model was employed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of pathological nodal features. Propensity score matching (PSM) was used to assess effect of adjuvant chemoradiotherapy (ACRT).
Among 518 curative-intent OTSCC patients, the number of PLNs independently predicted overall survival (OS), surpassing other pathological nodal features, including extranodal extension, laterality, and lower neck involvement. Patients with 1 or 2 PLNs had comparable worse OS than those with no PLN (median OS of 1 PLN vs. 2 PLNs vs. 0 PLN: 35.1 vs. 30.5 vs. 40.2 months), but better than those with ≥ 3 PLNs (median OS of 1-2 PLNs vs. 3 PLNs: 32.1 vs. 19.0 months). A proposed nodal category with 0, 1-2 PLNs, and ≥ 3 PLNs exhibited increasingly worse OS (HR of 1-2 PLNs and ≥ 3 PLNs vs. 0 PLN: 2.98 [95% CI: 1.89-4.71], p < 0.001; 5.47 [95% CI: 3.33-9], p < 0.001; respectively) and showed improved prediction power versus current pN staging (C-index: 0.717 vs. 0.713, p < 0.001). PSM analysis revealed that ACRT benefited patients with advanced nodal disease (≥ 3 PLNs) and improved OS. These findings were validated in SEER registry.
The number of PLNs is a better predictor of overall tumor burden for OTSCC and could be a more accurate metric for survival estimation, which should be considered in future simplified pathological nodal staging for better risk stratification and decision-making in subsites of the oral cavity.
探讨阳性淋巴结数量对口腔舌鳞状细胞癌(OTSCC)患者长期生存及病理淋巴结分期的影响。
确定2010年1月至2020年12月期间接受根治性切除的新诊断且无转移的成年OTSCC患者。通过监测、流行病学与最终结果(SEER)登记处进行外部验证。采用多变量Cox比例风险模型计算病理淋巴结特征的风险比(HR)和95%置信区间(CI)。倾向评分匹配(PSM)用于评估辅助放化疗(ACRT)的效果。
在518例有治愈意向的OTSCC患者中,阳性淋巴结数量独立预测总生存期(OS),优于其他病理淋巴结特征,包括结外扩展、侧别和下颈部受累情况。有1个或2个阳性淋巴结的患者的OS比无阳性淋巴结的患者差,但优于有≥3个阳性淋巴结的患者(1个阳性淋巴结、2个阳性淋巴结和0个阳性淋巴结的中位OS分别为35.1个月、30.5个月和40.2个月;1 - 2个阳性淋巴结与3个阳性淋巴结的中位OS分别为32.1个月和19.0个月)。一个提议的淋巴结分类为0个、1 - 2个阳性淋巴结和≥3个阳性淋巴结,其OS越来越差(1 - 2个阳性淋巴结和≥3个阳性淋巴结与0个阳性淋巴结相比的HR分别为2.98 [95% CI:1.89 - 4.71],p < 0.001;5.47 [95% CI:3.33 - 9],p < 0.001),并且与当前的pN分期相比,预测能力有所提高(C指数:0.717对0.713,p < 0.001)。PSM分析显示,ACRT使有晚期淋巴结疾病(≥3个阳性淋巴结)的患者受益并改善了OS。这些发现在SEER登记处得到验证。
阳性淋巴结数量是OTSCC总体肿瘤负荷的更好预测指标,可能是生存估计的更准确指标,在未来口腔亚部位简化病理淋巴结分期中应予以考虑,以实现更好的风险分层和决策。